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Abstract
Background: Maternal infections are associated with maternal and foetal adverse outcomes. Nutrient supplementation
during pregnancy may reduce the occurrence of infections by improving maternal immunity. We aimed to investigate
the impact of small-quantity lipid-based nutrient supplement (SQ-LNS) on the occurrence of Plasmodium falciparum
parasitaemia during pregnancy and trichomoniasis, vaginal candidiasis and urinary tract infection (UTI) after delivery.
Methods: Pregnant Malawian women enrolled in the iLiNS-DYAD trial receiving daily supplementation with SQ-LNS,
multiple micronutrients (MMN) or iron & folic acid (IFA) from <20 gestation weeks (gw) were assessed for P. falciparum
parasitaemia at 32 gw using rapid diagnostic testing (RDT), at 36 gw using polymerase chain reaction (PCR) and at
delivery using both RDT and PCR; and at one week after delivery for trichomoniasis and vaginal candidiasis using wet
mount microscopy and for UTI using urine dipstick analysis. The prevalence of each infection by intervention group was
estimated at the prescribed time points and the global null hypothesis was tested using logistic regression. Adjusted
analyses were performed using preselected covariates.
Results: The prevalence of P. falciparum parasitaemia was 10.7% at 32 gw, 9% at 36 gw, and 8.3% by RDT and 20.2% by
PCR at delivery. After delivery the prevalence of trichomoniasis was 10.5%, vaginal candidiasis was 0.5%, and UTI was 3.
1%. There were no differences between intervention groups in the prevalence of any of the infections.
Conclusion: In this population, SQ-LNS did not influence the occurrence of maternal P. falciparum parasitaemia,
trichomoniasis, vaginal candidiasis or UTI.
Trial registration: Identifier: NCT01239693 (10 November 2010).
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Background
Between 1990 and 2011 it was estimated that about 32%
of pregnant women attending antenatal clinics in East
and Southern Africa had peripheral malaria parasitaemia
[1]. Most of these infections, which are usually asymp-
tomatic, are caused by Plasmodium falciparum and may
lead to maternal anaemia [2] and low birth weight (LBW)
[3, 4]. Reproductive tract infections (RTIs) caused by
Trichomonas vaginalis and Candida albicans and urinary
tract infection (UTI) are also very common among preg-
nant women in this region and they have been associated
with the occurrence of preterm birth [4–9]. LBW and
preterm birth have adverse consequences for neonatal
survival, subsequent childhood mortality and impaired
motor and cognitive development [10–12].
Both P. falciparum infection and RTIs may be modified
by preventive measures or presumptive treatment during
pregnancy [13, 14]. For the prevention of malaria infection
in pregnancy, the World Health Organisation recom-
mends the use of long-lasting insecticidal nets (LLINs)
and in areas of stable transmission in sub-Saharan Africa,
intermittent preventive treatment in pregnancy with sul-
phadoxine pyrimethamine (IPT-SP) [15]. While there are
no recommendations for the prevention of RTIs during
pregnancy, programs that screen and treat RTIs early in
pregnancy have been associated with a decline in the
occurrence of preterm birth and LBW [16]. Nevertheless,
these prevention approaches have their own challenges
including vector resistance to pyrethroid, the main insecti-
cide used in malaria control [17]; P. falciparum resistance
to SP [18]; and the risk of the development of widespread
antibiotic resistance by bacterial organisms [19] if routine
antibiotic use for the prevention of RTIs was adopted. For
these reasons alternative methods for the prevention of
maternal infections such as nutritional interventions are
sought. Provision of small-quantity lipid-based nutrient
supplements (SQ-LNS) is a novel nutritional intervention
that supplies multiple micronutrients (MMN) and some
key macronutrients such as essential fatty acids (EFAs)
embedded in a lipid base [20]. When provided during
Fig. 1 Study participant flow diagram
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pregnancy, SQ-LNS have been shown to improve foetal
growth in Ghana [21] and Bangladesh [22] and birth
length in Burkina Faso [23]. However, no study has looked
at the impact of antenatal provision of SQ-LNS on mater-
nal infections.
To investigate the impact of SQ-LNS on maternal
infections we measured the prevalence of maternal P.
falciparum parasitaemia during pregnancy and at deliv-
ery and the prevalence of RTIs (trichomoniasis and vagi-
nal candidiasis) and bacterial UTI after delivery among
women in Mangochi, Malawi who were enrolled into a
randomised, controlled trial that provided iron and folic
acid (IFA), MMN or SQ-LNS daily [24]. We hypothe-
sized that gestational SQ-LNS supplementation would
reduce the prevalence of P. falciparum parasitaemia
during pregnancy and the prevalence of RTIs after deliv-
ery compared to MMN and IFA. We based our assump-
tions on the knowledge that derivatives of the EFAs such
as eicosapentaenoic acid, docosahexaenoic acid and
arachidonic acid have antimalarial, antitrichomonal and
antifungal properties [25–27].
Methods
The study methods have been described in detail else-
where [24]. Briefly, this study was a sub-study of the
iLiNS-DYAD-M trial, an outcome assessor-blinded ran-
domised controlled trial that provided antenatal nutrient
supplementation to improve pregnancy outcomes and
child growth (trial registration: www.clinicaltrials.gov,
trial identification NCT01239693). We recruited the
study participants from antenatal clinics at four health
facilities in Mangochi District, southern Malawi. Pregnant
women were eligible to participate in the study if they
were at least 15 years old, had ultrasound-confirmed preg-
nancy of <20 gestation weeks (gw), had no chronic med-
ical condition or allergies and no evident pregnancy
complications. The catchment population was rural to
semi-urban and subsisted mainly on fishing and farm-
ing. Maize was the staple food in this population,
which faces seasonal food insecurity with a lean
period just before harvest time. Malaria transmission
was holoendemic in this area.
The enrolled women were randomised into three
intervention groups receiving either one tablet of IFA,
the standard antenatal nutrient supplement in Malawi;
one tablet of MMN which contained 18 micronutrients
(including iron and folic acid) or one 20 g sachet of
SQ-LNS containing the same 18 micronutrients and
four additional minerals, EFAs (linoleic acid and α-
linolenic acid), protein, fat and 1.2 g of sucrose daily
from enrolment to delivery [24]. The dose of iron was
higher for women in the IFA group (60 mg) than for
those in the MMN and SQ-LNS groups (20 mg). The
lower iron dose in SQ-LNS was chosen so as not to
greatly exceed the recommended daily intake of iron
for lactating women [28], and because a dose of 20 mg/
day has in some conditions been sufficient for prevent-
ing iron deficiency anaemia in pregnancy [20, 29]. The
doses of the rest of the micronutrients in the MMN
and SQ-LNS supplements were at least the recom-
mended dietary allowance (RDA) for pregnancy, or the
maximum amount that could be included in the sup-
plement considering technical constraints [20]. The
exact ingredients and dosing of the study supplements
are shown in Additional file 1: Table S1. The partici-
pants also received two doses of IPT-SP according to
the Malawi national guidelines at the time, which
were concordant with the World Health Organisa-
tion’s recommendations [30].
The outcomes reported here were pre-specified sec-
ondary outcomes measures. These were peripheral P.
falciparum parasitaemia; trichomoniasis; vaginal candid-
iasis; and bacterial UTI. We diagnosed P. falciparum
parasitaemia by rapid diagnostic testing (RDT) at 32 gw,
by polymerase chain reaction (PCR) at 36 gw and by
RDT and PCR at delivery. RDT at 32 gw was assessed
from finger prick blood samples whereas PCR at 36 gw
and RDT and PCR at delivery were assessed from venous
blood samples. Study nurses performed RDT according
to the manufacturer’s instructions using Clearview®
Malaria Combo (British Biocell International Ltd.,
Dundee, UK) which detects the antigens histidine-rich
protein 2 and Plasmodium-specific aldolase. We con-
ducted PCR testing for P. falciparum on dried blood
spot samples collected from whole blood, which were
tested in a real-time PCR assay targeting the P. falcip-
arum lactate dehydrogenase (pfldh) gene [31].
RTIs and UTIs were assessed at one week after deliv-
ery using samples from vaginal swabs and mid-stream
urine, respectively. The study participant was lying in
the dorsal lithotomy position for the collection of the va-
ginal samples. After digitally separating the labia, a study
nurse advanced a cotton tipped swab through the vagi-
nal introitus towards the posterior fornix and rotated
the sample back and forth three times before pulling it
out. Then the vaginal samples were sent to the labora-
tory where a laboratory technician processed them im-
mediately by smearing the vaginal discharge from the
swab on a microscope slide and performed wet mount
microscopy after adding saline solution. We defined
trichomoniasis as the visualisation of motile protozoa
and candidiasis as the observation of budding yeasts,
pseudohyphae or hyphal forms on microscopy. The
study nurse performed urinalysis immediately after
urine collection using Multistix ® 10 SG reagent strip
(Siemens Medical Solutions USA, Inc., Pennsylvania,
USA) and UTI was indicated by the presence of nitrite
in a freshly voided urine sample [32].
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A sample size of 1400 was originally calculated in ac-
cordance with the main objectives of the iLiNS-DYAD-
M trial. This sample size provided 80% power and 95%
confidence to detect an approximately 30% reduction
(among the women who received SQ-LNS, as compared
to the control women) in the prevalence of maternal
RTIs (from 25 to 18.3%) or P. falciparum parasitaemia
(from 15 to 9.5%). We conducted statistical analyses
using Stata 12.1 (StataCorp, College Station, USA), ac-
cording to an analysis plan written and published before
the intervention code was opened [24]. The analysis was
based on the principle of intention-to-treat.
We estimated the prevalence of maternal P. falciparum
parasitaemia (by intervention group) at 32 gw, 36 gw and
delivery and we estimated the prevalence of the RTIs (by
intervention group) at one week after delivery. We
calculated Risk Ratios (RRs) for the comparison of binary
end-points at a single time point and computed 95%
confidence intervals (CIs) for all the effect estimates.
We performed tests for interaction between the inter-
vention, maternal infection and pre-specified covariates
using the likelihood ratio test. The pre-specified covari-
ates were maternal age, maternal parity, gestational age
at enrolment, socio-economic score, education (com-
pleted years at school) and body-mass-index (BMI) as
continuous variables; HIV status, P. falciparum parasit-
aemia, anaemia, season at enrolment and study site as
categorical variables. We performed stratified analyses
for all covariates that had a statistically significant inter-
action (p < 0.1).
The study protocol was approved by the College of
Medicine Research and Ethics Committee, University of
Malawi and the Ethics Committee of Pirkanmaa Hospital
District, Finland. The trial was performed according to
Good Clinical Practice guidelines and the ethical standards
of Helsinki Declaration. Study staff obtained informed con-
sent from the study participants (or their legal guardian in
the case of minors) prior to performing any study proce-
dures. An independent data safety and monitoring board
monitored the incidence of suspected serious adverse
events and performed interim analyses for safety.
Results
We recruited a total of 1391 pregnant women into the
iLiNS-DYAD-M study between February 2011 and August
2012. The last delivery occurred in February 2013. The
three groups were similar at baseline in terms of the
participants’ average demographic and socioeconomic
characteristics and nutritional and health status (p > 0.05)
(Table 1). The overall rate of usage of LLINs was 70.9%
and was similar across the groups (P = 0.536). We ex-
cluded 12 women from the analysis because they had twin
pregnancies.
Follow up data for P. falciparum parasitaemia were
available from 79.6% of the women at 32 gw, 76.9% at 36
gw, and from 81.4 and 78.7% at delivery by RDT and
PCR respectively. Loss to follow up was similar between
the groups (P = 0.805 at 32 gw, 0.638 at 36 gw, 0.180
and 0.393 for P. falciparum parasitaemia RDT and PCR
at delivery). RTI and UTI data were collected from
Table 1 Baseline characteristics of the participating women at enrolment, by intervention group
Characteristic IFA MMN LNS
Number of participants 463 466 462
Mean (SD) maternal age, years 25 (6) 25 (6) 25 (6)
Mean (SD) maternal education, completed years 3.9 (3.4) 4.1 (3.4) 4.1 (3.6)
Proportion with severely food insecure households 34.7% 37.5% 35.8%
Mean (SD) gestational age at enrolment, weeks 16.8 (2.1) 16.8 (2.2) 16.9 (2.2)
Mean (SD) number of previous pregnancies 2.1 (1.8) 2.1 (1.8) 2.2 (1.7)
Proportion of nulliparous women 20.4% 23.0% 22.1%
Mean (SD) height, cm 156.1 (5.7) 156.0 (5.6) 156.1 (5.7)
Mean (SD) weight, kg 53.9 (7.4) 54.0 (8.1) 54.3 (8.4)
Mean (SD) MUAC, cm 26.4 (2.4) 26.3 (2.8) 26.5 (2.7)
Mean (SD) BMI, kg/m2 22.1 (2.6) 22.2 (2.9) 22.2 (3.0)
Proportion of women with a BMI < 18.5 kg/m2 5.9% 4.6% 5.7%
Mean (SD) blood haemoglobin concentration, g/l 111 (17) 111 (16) 112 (16)
Proportion of anaemic women (Hb < 100 g/l) 21.0% 19.8% 21.2%
Proportion of women with a positive HIV test 15.6% 11.1% 14.4%
Proportion of women with a positive P. falciparum test (RDT) 22.7% 24.1% 22.8%
IFA iron and folic acid, LNS lipid based nutrient supplement, MMN multiple micronutrients, MUAC mid-upper arm circumference, RDT rapid diagnostic test
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86.6% of the women. Loss to follow up was similar be-
tween the groups (P = 0.958 for RTI and UTI after deliv-
ery) (Fig. 1). The participants who were excluded from
the analysis tended to be younger (23.8 vs 25.4, P <
0.001); to be more educated (4.4 vs 3.9, P = 0.025); to
have a slightly higher BMI (22.6 vs 22.0, P = 0.001); to
have a higher wealth index (0.29 vs −0.09, P < 0.001); to
be primiparous (31% vs 18%, P < 0.001) and to be an-
aemic (25% vs 19%, P = 0.014).
The overall prevalence of P. falciparum parasitaemia
was 23.3% at enrolment (RDT), 10.7% at 32 gw (RDT);
9.0% at 36 gestation weeks (PCR); 8.3% by RDT at deliv-
ery and 20.2% by PCR at delivery. The prevalence of P.
falciparum parasitaemia at 32 gw (RDT), 36 gw (PCR),
delivery (RDT) and delivery (PCR) was 10.9, 7.6, 8.0 and
17.6%, respectively, in the LNS group, and was similar in
the IFA and MMN groups (Table 2). Relative to the IFA
group, the risk for P. falciparum parasitaemia.at 32 gw
(RDT) was not significantly different in the SQ-LNS (RR
0.91, 95% CI 0.6- 1.36) or MMN (RR 0.79, 95% CI 0.52-
1.20) groups. Similarly, when compared to MMN, the
risk for P. falciparum parasitaemia at 32 gw (RDT) in
the LNS group was not significantly different (RR 1.14,
95% CI 0.74- 1.76). The risk for P. falciparum parasit-
aemia at the other time points was also similar in all 3
study groups (Table 2).
The overall prevalence of trichomoniasis, candidiasis
and UTI after delivery was 10.5, 0.5 and 3.1% respect-
ively. The prevalence of trichomoniasis, candidiasis and
UTI was 8.3, 0.3, 3.2% respectively, in the LNS group,
and was similar in the IFA and MMN groups (Table 3).
Relative to the IFA group, the risk for trichomoniasis
was not significantly different in the SQ-LNS (RR 0.71,
95% CI 0.47- 1.09) or MMN (RR 0.93, 95% CI 0.63-
1.37) groups. Similarly, when compared to MMN, the
risk for trichomoniasis in the LNS group was not signifi-
cantly different (RR 0.77, 95% CI 0.50- 1.18). The risk
for UTI was also similar in all 3 study groups (Table 3).
The risk ratio for candidiasis was not calculated because
the prevalence of candidiasis was very low.
Tests of interaction with potential effect modifiers were
not significant (P > 0.1) for maternal age, maternal parity,
socio-economic score, HIV status, anaemia, season at en-
rolment and study site, but were significant for at least
one outcome for gestational age at enrolment, maternal
BMI, maternal education and baseline P. falciparum para-
sitaemia. Gestational age at enrolment modified the asso-
ciation between the intervention group and P. falciparum
parasitaemia by RDT at 32 gw (P = 0.024); maternal BMI
modified the association between the intervention group
and trichomoniasis (P = 0.039): maternal education modi-
fied the association between the intervention group and P.
falciparum by RDT at delivery (P = 0.048) and baseline P.
falciparum parasitaemia modified the association between
the intervention group and P. falciparum parasitaemia at
delivery (by both RDT and PCR, P = 0.058 and 0.078 re-
spectively). However, there were no statistically significant
differences between the intervention groups in any of the
strata (Additional file 2: Table S2).
Discussion
We investigated whether the provision of SQ-LNS dur-
ing pregnancy affects the occurrence of P. falciparum
parasitaemia and RTIs among women in a population
with generally poor food security. Overall, we found no
statistically significant differences in the prevalence of
maternal P. falciparum parasitaemia and RTIs between
the study intervention groups.
The probabilities of bias or random error in this study
were minimised by the large sample size, randomised
study design, blinding of outcome assessors and inclusion
of several P. falciparum parasitemia measurements using
sensitive detection methods (RDT and PCR) [31, 33]. The
success of follow-up was not complete, due to loss of par-
ticipants during the follow up or missed visits or biological
samples, but the proportion of missing data was simi-
lar across the study groups and several adjusted ana-
lyses gave results similar to the main analysis; hence
we believe that the missing data did not significantly
bias our conclusions. The excluded participants were,
Table 2 Prevalence of maternal P. falciparum parasitaemia in Malawian women given IFA, MMN and LNSa
Outcome IFA MMN LNS LNS vs. IFA LNS vs. MMN MMN vs. IFA
P. falciparum parasitaemia
at 32 gw (RDT)
12.0 (8.7–15.3) (374)a 9.5 (6.6–12.5) (377) 10.9 ( 7.7–14.2) (357) 0.91 (0.61–1.36) 1.14 (0.74–1.76) 0.79 (0.52–1.20)
P. falciparum parasitaemia
at 36 gw (PCR)
10.8 (7.5–14.1) (352) 8.5 (5.6–11.4) (363) 7.6 (4.8–10.4) (355) 0.70 (0.44–1.13) 0.89 (0.54–1.46) 0.79 (0.50–1.24)
P. falciparum parasitaemia
at delivery (RDT)
9.1 (6.2–12.0) (373) 7.8 (5.1–10.5) (372) 8.0 (5.3–10.8) (386) 0.88 (0.55–1.40) 1.03 (0.63–1.67) 0.86 (0.53–1.37)
P. falciparum parasitaemia
at delivery (PCR)
20.6 (16.5–24.7) (369) 22.4 (18.0–26.8) (357) 17.6 (13.7–21.5) (369) 0.86 (0.63–1.15) 0.79 (0.59–1.05 1.09 (0.82–1.44)
aValues are percentages (95% CIs) (n) or risk ratios (95% CIs). IFA iron folic acid, MMN multiple micronutrients, LNS lipid based nutrient supplements, RDT rapid
diagnostic testing, PCR polymerase chain reaction
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however somewhat different from those included in
the analysis in terms of some of their anthropometric,
sociodemographic and health characteristics. For these
reasons our results may not be fully representative of
the target population. Furthermore, the methods that
we used to detect vaginal candidiasis, trichomoniasis
and bacterial UTI have low to moderate sensitivity
[34–36]. This may have led us to underestimate the
burden of these conditions in our study population.
Finally, the prevalence of each infection (except for P.
falciparum parasitaemia at 36gw by PCR) was lower
than what we had estimated in our sample size calcu-
lation, potentially affecting our power calculations.
However, as argued by Feinstein and Concato [37],
our point estimates and confidence intervals were
consistently in the same direction and sufficiently pre-
cise to conclude that SQ-LNS supplementation did
not influence the prevalence of maternal P. falcip-
arum parasitemia or RTIs in rural Malawi, though we
cannot conclusively rule out an effect on the preva-
lence of candidiasis and UTI.
The prevalence of P. falciparum parasitemia at deliv-
ery was much higher based on PCR testing compared to
RDT among the study women. This finding was not un-
usual and it was probably due to low parasite density in
the study population. The sensitivity of RDT tests varies
with parasite density, with lower sensitivity at lower
parasite density [38].
The prevalence of P. falciparum parasitaemia by RDT
continued to decline from enrolment through 32 gesta-
tional weeks to delivery in our study population. This
finding is unsurprising as similar results were obtained
from women who received two doses of IPT-SP in a pre-
vious study conducted in the same study area [14] and
from elsewhere in sub-Saharan Africa [39]. Assuming no
loss to follow-up in our study, we would expect the
prevalence of P. falciparum parasitaemia in pregnancy
to drop in the period following enrolment into the study
as the women were exposed to anti-malaria interven-
tions such as IPT-SP and receipt of LLINs as part of the
ante-natal care package.
Little is known about the effect of SQ-LNS on mater-
nal health or morbidity. Other reports from the iLiNS-
DYAD trial suggested that SQ-LNS and MMN may have
increased the risk of maternal dental infections [40] on
one hand but seemed to have had no effect on the devel-
opment of maternal anti-malarial antibodies [41] on the
other hand. Previous in vitro studies have suggested that
EFAs and their derivatives such as arachidonic acid and
docosahexaenoic acid may have toxic effects on P. falcip-
arum [42], T. vaginalis [43] and C. albicans [27] via
different mechanisms, hence our expectation that pro-
viding SQ-LNS which contained EFAs would reduce the
prevalence of infections caused by these organisms. The
apparent lack of benefit from the EFAs in this study
could have happened because the study women were
not deficient in EFAs to begin with. A recently published
trial conducted in the same study area as our study
found that the levels of breast milk arachidonic acid and
docosahexaenoic acid were above average levels [44]
contrary to our earlier assumptions based on previous
studies in sub-Saharan Africa [45]. Alternatively, the
absence of influence of SQ-LNS on maternal plasma
composition of EFAs (Oaks et al., in press) could explain
our observation of lack of impact.
A previous study that provided combined vitamin A
and zinc supplementation to children in Ghana led to a
reduction in the risk of clinical malaria episodes [46]
possibly due to the synergistic effects of vitamin A and
zinc on immune function [47]. Contrary to our expect-
ation based on these previous studies, SQ-LNS and
MMN which contained both vitamin A and zinc were
not associated with a lower risk of P. falciparum parasit-
aemia. The lack of treatment response despite the
provision of adequate doses of vitamin A and zinc in
MMN and SQ-LNS and reasonable adherence to supple-
mentation [24] could have been due to dietary factors
inhibiting zinc absorption [48] or haemodilution in the
latter half of pregnancy lowering levels of retinol binding
protein resulting in functional vitamin A deficiency [49].
Conclusion
Taken together, the study findings do not support our
hypothesis that the provision of antenatal SQ-LNS
would reduce the prevalence of P. falciparum parasit-
aemia during pregnancy and the prevalence of RTIs after
delivery compared to supplementation with MMN or
IFA. Whether or not a target population is deficient in
EFAs might be an important factor in determining
whether SQ-LNS provision to pregnant women can
Table 3 Prevalence of reproductive tract infections after delivery in Malawian women given IFA, MMN and LNSa
Outcome IFA MMN LNS LNS vs. IFA LNS vs. MMN MMN vs. IFA
Prevalence of trichomoniasis 11.6 (8.5–14.7) (405)a 10.8 (7.8–13.8) (407) 8.3 (5.6–11.0) (398) 0.71 (0.47–1.09) 0.77 (0.50–1.18) 0.93 (0.63–1.37)
Prevalence of candidiasis 0.2 (−0.2–0.7%) (406) 1.0 (0.0–1.9) (409) 0.3 (−0.2–0.7) (399) – – –
Prevalence of UTI 2.2 (0.7–3.7) (406) 3.7 (1.9–5.6) (405) 3.2 (1.5–5.0) (401) 1.46 (0.63–3.38) 0.86 (0.42–1.82) 1.67 (0.74–3.77)
aValues are percentages (95% CIs) (n) or risk ratios (95% CIs). IFA iron folic acid, MMN multiple micronutrients, LNS lipid based nutrient supplements, UTI urinary
tract infection
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influence the occurrence of maternal infections. Use of
more sensitive diagnostic methods such as culture,
antigen or PCR tests for the detection of RTIs and UTI
may improve outcome ascertainment in future studies.
Further clinical trials supplementing single nutrients
(EFAs, vitamin A or zinc) may be crucial in isolating the
impact of each nutrient on maternal infections.
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